XBI240719C74000
- 19.25
- 0.000.00%
SPDR S&P Biotech ETF Newsroom
Viridian, Pharvaris Said to Be Among Prime M&A Targets for Biogen
Unpacking the Latest Options Trading Trends in Amgen
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:AMGN) revealed 18 unusual trades.Delving into the details, we found 22% of traders
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
In today's rapidly changing and fiercely competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies. In this article, we will conduct a
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $28,000 Today
United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 20 years by 9.58% on an annualized basis producing an average annual return of 18.13%. Currently, United Therapeutics has
Gilead Highlights Progress In Research Across HIV Prevention, Treatment And Cure Programs At AIDS 2024
- Late-Breaking Full Results from HIV Prevention Research of Twice-Yearly Injectable Lenacapavir -- Progress and Person-Centered Approaches Across HIV Treatment, Cure Research and Development
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Sen. Bernie Sanders (I-Vt.) recently expressed his concerns about the high cost of medical care in the United States, highlighting the financial burden it places on patients.
A Closer Look at Amgen's Options Market Dynamics
Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ:AMGN).And retail traders should know.We noticed this today when the trades showed up on publicly available options
Solid Biosciences up 10% Following J.P. Morgan Upgrade
Oppenheimer's Best SMID-cap Ideas: AI, Health, Obesity Drugs, and More
Lexeo Stock Drops 24% Amid Friedreich Ataxia Study Results
Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher by more than 100 points on Friday. Investors, meanwhile, focused on some notable insider trades.When insiders sell shares, it could be a preplanned sale, or could
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $255
Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price target from $250 to $255.
Alnylam Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/12/2024 -3.25% Morgan Stanley $250 → $255 Maintains Equal-Weight 07/08/2024 35.45% Canaccord Genuity $2
These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey
Biogen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/12/2024 32.35% Piper Sandler $335 → $313 Maintains Overweight 06/28/2024 24.32% Needham $294 → $294
This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment
The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals
Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Regeneron Pharmaceuticals (NASDAQ:REGN) in the last three months.The following table
Gilead Sciences's Options Frenzy: What You Need to Know
Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga